A new pooled analysis of the FIBRONEER™-IPF and FIBRONEER™-ILD trials resulted in a nominally significant reduction in the risk of death by 59% in patients who received 18mg nerandomilast without ...

Please provide your email address to receive an email when new articles are posted on . Within the studied cohort, males had a higher IPF death rate than females. Researchers observed eight industries ...

Boehringer Ingelheim established a presence in idiopathic pulmonary fibrosis years ago with a drug that has become a standard treatment for this serious lung disorder. Now the company has the ...

When breathing becomes increasingly difficult with no clear explanation, idiopathic pulmonary fibrosis (IPF) might be the culprit behind the concerning symptoms. This rare yet devastating lung disease ...

Researchers at Tulane University have identified a potential new way to treat idiopathic pulmonary fibrosis (IPF), a deadly and currently incurable lung disease that affects more than 3 million people ...

Please provide your email address to receive an email when new articles are posted on . Both the 18 mg and 9 mg nerandomilast groups had smaller degrees of FVC decline vs. placebo in the U.S. subgroup ...

Could targeting a enzyme play a role in slowing lung fibrosis? Boehringer Ingelheim’s research into PDE4B is offering ...